The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Innate Pharma S.A(NASDAQ:IPHA) 
Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tu...
Website: http://www.innate-pharma.com/en
Founded: 1999
IPO Price: $5.5 (Oct 17, 2019)
Full Time Employees: 247
CEO: Mondher Mahjoubi
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
Innate Pharma S.A Days Payable Outstanding ttm (DPO)
Innate Pharma S.A Days Receivable Outstanding ttm (DSO)
Innate Pharma S.A Days Inventory Outstanding ttm (DIO)
Innate Pharma S.A Op Cashflow Per Share ttm
Innate Pharma S.A Free Cashflow Per Share ttm
Innate Pharma S.A Cash Per Share ttm
Innate Pharma S.A P/S ratio ttm
Innate Pharma S.A (GAAP) P/E ratio ttm
Innate Pharma S.A P/B ratio ttm
No extra charts and metrics for this ticker.